Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Evommune Inc shares valued at $17,350 were purchased by Hopfner Robert Lorne on Dec 19 ’25. At $17.35 per share, Hopfner Robert Lorne acquired 1,000 shares. The insider’s holdings grew to 4,026 shares worth approximately $70817.34 following the completion of this transaction.
As published in their initiating research note from William Blair on December 01, 2025, Evommune Inc [EVMN] has been an Outperform. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in early December. As of December 01, 2025, Leerink Partners has initiated its “an Outperform” rating for EVMN. Earlier on December 01, 2025, Evercore ISI initiated its rating. Their recommendation was “an Outperform” for EVMN stock.
Analyzing EVMN Stock Performance
On last trading session, Evommune Inc [NYSE: EVMN] plunged -1.79% to $17.59. The stock’s lowest price that day was $17.43, but it reached a high of $18.2976 in the same session. During the last five days, there has been a surge of approximately 10.49%.
Support And Resistance Levels for Evommune Inc (EVMN)
According to the 24-hour chart, there is a support level at 17.21, which, if violated, would cause prices to drop to 16.84. In the upper region, resistance lies at 18.18. The next price resistance is at 18.78. RSI (Relative Strength Index) is 45.67 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Evommune Inc (EVMN)?
In terms of Evommune Inc share price expectations, FactSet research, analysts set an average price target of 40 in the next 12 months, up nearly 123.34% from the previous closing price of $17.91. Analysts anticipate Evommune Inc stock to reach 42 by 2025, with the lowest price target being 36.
